Search Within

Benjamin Diamond

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (6)
  3. Review (2)
  4. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (18)
  2. Department of Medicine (18)
  3. Department of Pathology and Laboratory Medicine (18)
  4. Hematologic Malignancies, Division of (18)
  5. Hematology-Oncology Fellows (18)
  6. Myeloma (18)

More Groups

People
  1. Ahmet Dogan (16)
  2. Malin Hultcrantz (16)
  3. Carl Landgren (14)
  4. Even Rustad (13)
  5. Kylee Maclachlan (13)
  6. Francesco Maura (12)

More People

Years
  1. 2023 (1)
  2. 2021 (9)
  3. 2020 (8)
Publications
  1. Blood (6)
  2. Nature Communications (3)
  3. American Journal of Hematology (1)
  4. Blood Cancer Discovery (1)
  5. Blood Reviews (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. Nature Publishing Group (3)
  3. American Association for Cancer Research (2)
  4. Elsevier Science, Inc. (2)
  5. Royal College of Pathologists of Australasia (1)
  6. American Medical Association (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
    Journal Article

    Maclachlan, K. H.; Rustad, E. H.; Derkach, A.; Zheng-Lin, B.; Yellapantula, V.; Diamond, B.; Hultcrantz, M.; Ziccheddu, B.; Boyle, E. M.; Blaney, P.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
    Journal Article

    Maura, F.; Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V. D.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Minimal residual disease in multiple myeloma: Defining the role of next generation sequencing and flow cytometry in routine diagnostic use
    Review

    Maclachlan, K. H.; Came, N.; Diamond, B.; Roshal, M.; Ho, C.; Thoren, K.; Mayerhoefer, M. E.; Landgren, O.; Harrison, S.
    Pathology (2021)

    Fulltext@MSK | Save
  • Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
    Journal Article

    Oben, B.; Froyen, G.; Maclachlan, K. H.; Leongamornlert, D.; Abascal, F.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Geerdens, E.; Diamond, B. T.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
    Review

    Diamond, B. T.; Rustad, E.; Maclachlan, K.; Thoren, K.; Ho, C.; Roshal, M.; Ulaner, G. A.; Landgren, C. O.
    Blood Reviews (2021)

    Fulltext@MSK | Save
  • Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: Feasibility, challenges, and direct comparison with high-sensitivity flow cytometry
    Journal Article

    Ho, C.; Syed, M.; Roshal, M.; Petrova-Drus, K.; Moung, C.; Yao, J.; Quesada, A. E.; Benhamida, J.; Vanderbilt, C.; Liu, Y.; more...
    Journal of Molecular Diagnostics (2021)

    Fulltext@MSK | Save